Open AccessQuantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
Author(s) -
S. Vonk,
Marloes van der Meer-Vos,
Lieuwe D. J. Bos,
Anne H. Neerincx,
Christof J. Majoor,
AnkeHilse Maitlandvan der Zee,
Ron A. A. Mathôt,
E. Marleen Kemper
Publication year - 2021
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000829
Subject(s) - ivacaftor , chromatography , tandem mass spectrometry , hydroxymethyl , sputum , chemistry , mass spectrometry , medicine , cystic fibrosis , pathology , tuberculosis , stereochemistry , cystic fibrosis transmembrane conductance regulator
The novel cystic fibrosis transmembrane conductance regulator (CFTR) modulators, ivacaftor, lumacaftor, and tezacaftor, are the first drugs directly targeting the underlying pathophysiological mechanism in cystic fibrosis (CF); however, independent studies describing their pharmacokinetics are lacking. The aim of this study was to develop a quantification method for ivacaftor and its 2 main metabolites, lumacaftor and tezacaftor, in plasma and sputum using liquid chromatography with tandem mass spectrometry.